These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35587447)

  • 21.
    Menetrey Q; Sorlin P; Jumas-Bilak E; Chiron R; Dupont C; Marchandin H
    Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33919046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Achromobacter xylosoxidans: characterization of strains in Brazilian cystic fibrosis patients.
    Pereira RH; Carvalho-Assef AP; Albano RM; Folescu TW; Jones MC; Leão RS; Marques EA
    J Clin Microbiol; 2011 Oct; 49(10):3649-51. PubMed ID: 21849686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Achromobacter xylosoxidans: an emerging pathogen carrying different elements involved in horizontal genetic transfer.
    Traglia GM; Almuzara M; Merkier AK; Adams C; Galanternik L; Vay C; Centrón D; Ramírez MS
    Curr Microbiol; 2012 Dec; 65(6):673-8. PubMed ID: 22926720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients.
    Raso T; Bianco O; Grosso B; Zucca M; Savoia D
    APMIS; 2008 Sep; 116(9):837-41. PubMed ID: 19024606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic insights into intrinsic and acquired drug resistance mechanisms in Achromobacter xylosoxidans.
    Hu Y; Zhu Y; Ma Y; Liu F; Lu N; Yang X; Luan C; Yi Y; Zhu B
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1152-61. PubMed ID: 25487802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal Surveillance and Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant
    Okoliegbe IN; Hijazi K; Cooper K; Ironside C; Gould IM
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816722
    [No Abstract]   [Full Text] [Related]  

  • 27. Presence of OXA-type enzymes in Achromobacter insuavis and A. dolens.
    Traglia G; Papalia M; Almuzara M; Gutkind G; Centrón D; Vay C; Radice M; Ramírez MS
    Curr Microbiol; 2014 Oct; 69(4):501-6. PubMed ID: 24894902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Achromobacter xylosoxidans Bacteremia and Cellulitis: A Report of a Case.
    Dai J; Huen AO; Kestenbaum LA; Sarezky MD; Coughlin CC; Yan AC
    Pediatr Dermatol; 2015; 32(4):e186-7. PubMed ID: 25973735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients.
    Lambiase A; Catania MR; Del Pezzo M; Rossano F; Terlizzi V; Sepe A; Raia V
    Eur J Clin Microbiol Infect Dis; 2011 Aug; 30(8):973-80. PubMed ID: 21279730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemic Achromobacter xylosoxidans strain among Belgian cystic fibrosis patients and review of literature.
    Cools P; Ho E; Vranckx K; Schelstraete P; Wurth B; Franckx H; Ieven G; Van Simaey L; Van Daele S; Verhulst S; De Baets F; Vaneechoutte M
    BMC Microbiol; 2016 Jun; 16(1):122. PubMed ID: 27342812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data.
    Amoureux L; Bador J; Siebor E; Taillefumier N; Fanton A; Neuwirth C
    J Cyst Fibros; 2013 Mar; 12(2):170-6. PubMed ID: 22944724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mediastinitis superinfected by Achromobacter xylosoxidans. A case report.
    Marion-Sanchez K; Lion F; Olive C; Cailleaux G; Roques F
    J Infect Chemother; 2018 Dec; 24(12):987-989. PubMed ID: 29895453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluorescence in situ hybridization for rapid identification of Achromobacter xylosoxidans and Alcaligenes faecalis recovered from cystic fibrosis patients.
    Wellinghausen N; Wirths B; Poppert S
    J Clin Microbiol; 2006 Sep; 44(9):3415-7. PubMed ID: 16954289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complicated intra-abdominal infection caused by extended drug-resistant Achromobacter xylosoxidans.
    Teng SO; Ou TY; Hsieh YC; Lee WC; Lin YC; Lee WS
    J Microbiol Immunol Infect; 2009 Apr; 42(2):176-80. PubMed ID: 19597652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An unusual skin infection with Achromobacter xylosoxidans.
    Crosby MD; Petropolis AA; Mackey VT; Culpepper KS
    Cutis; 2020 Oct; 106(4):2110-212. PubMed ID: 33186423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transmission and Antibiotic Resistance of
    Gabrielaite M; Bartell JA; Nørskov-Lauritsen N; Pressler T; Nielsen FC; Johansen HK; Marvig RL
    J Clin Microbiol; 2021 Mar; 59(4):. PubMed ID: 33472899
    [No Abstract]   [Full Text] [Related]  

  • 37. Achromobacter spp. prevalence and adaptation in cystic fibrosis lung infection.
    Veschetti L; Boaretti M; Saitta GM; Passarelli Mantovani R; Lleò MM; Sandri A; Malerba G
    Microbiol Res; 2022 Oct; 263():127140. PubMed ID: 35931003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis.
    Firmida MC; Pereira RH; Silva EA; Marques EA; Lopes AJ
    Braz J Med Biol Res; 2016; 49(4):e5097. PubMed ID: 26909788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematogenous pleural infection caused by Achromobacter xylosoxidans in a patient undergoing maintenance hemodialysis.
    Shimamura T; Yamashita S; Ryuujin S; Ogata T; Yamashita T; Sato A; Hitomi S
    J Infect Chemother; 2020 Apr; 26(4):389-392. PubMed ID: 31837898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center.
    Van Daele S; Verhelst R; Claeys G; Verschraegen G; Franckx H; Van Simaey L; de Ganck C; De Baets F; Vaneechoutte M
    J Clin Microbiol; 2005 Jun; 43(6):2998-3002. PubMed ID: 15956444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.